Literature DB >> 2956866

Potential mechanisms of improved left ventricular function with enoximone in severe congestive heart failure.

K Chatterjee, D Kereiakes, C Viquerat, R Podolin.   

Abstract

Enoximone, a phosphodiesterase inhibitor, is a potent inotropic vasodilator agent that causes a marked improvement in systemic hemodynamics in patients with severe chronic congestive heart failure. Cardiac index, stroke volume index and stroke work index increase, and there is a significant decrease in pulmonary capillary wedge pressure. Left ventricular dP/dt increases, despite a decrease in arterial pressure and systemic vascular resistance and without any significant change in heart rate, indicating a positive inotropic effect. A marked decrease in systemic vascular resistance indicates that decreased left ventricular outflow resistance resulting from peripheral vasodilation also contributes to improvement in left ventricular function. In some patients, left ventricular end-diastolic volume increases despite a marked decrease in pulmonary capillary wedge pressure, suggesting an improvement in apparent left ventricular compliance, which may also be contributory to improved left ventricular function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956866     DOI: 10.1016/0002-9149(87)90523-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration.

Authors:  V Mitrovic; O Petrovic; H Bahavar; J Neuzner; H A Dieterich; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

Review 2.  Enoximone. A review of its pharmacological properties and therapeutic potential.

Authors:  M W Vernon; R C Heel; R N Brogden
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  The new phosphodiesterase inhibitor enoximone in patients following cardiac surgery--pharmacokinetics and influence on parameters of coagulation.

Authors:  J Boldt; D Kling; H A Dieterich; P Marck; G Hempelmann
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.